Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug 10;13(8):1580.
doi: 10.3390/v13081580.

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Anita Y M Howe  1 , Francesca Ceccherini-Silberstein  2 , Julia Dietz  3 , Stephanie Popping  4 , Jason Grebely  5 , Chaturaka Rodrigo  6 , Johan Lennerstrand  7 , Mark W Douglas  8 , Milosz Parczewsk  9 , P Richard Harrigan  10 , Jean-Michel Pawlotsky  11 , Federico Garcia  12 , Shared Collaborators  1
Affiliations
Editorial

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Anita Y M Howe et al. Viruses. .

Abstract

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...].

PubMed Disclaimer

Conflict of interest statement

J.M.P. has been an advisor and/or speaker for Abbvie, Assembly Biosciences, Arbutus, Merck, Gilead, Regulus and Memo Therapeutics. J.D. receives research support from Gilead. A.Y.M.H. is a consultant for Boston Pharmaceuticals. J.G. reports grants and personal fees from Abbvie, Gilead Sciences, Merck, and Cepheid and grants from Hologic and Indivior, outside the submitted work.

Figures

Figure 1
Figure 1
Geographic locations of participating centers and patient cohorts in SHARED. Each dot represents a participating center (local clinic or reference laboratory) where patient sample sequences were generated. For samples from randomized clinical trials or international consortia, the dots represent the participating countries. The size of the dot represents the relative number of samples (not to scale).
See this image and copyright information in PMC

References

    1. Feld J.J., Jacobson I.M., Hézode C., Asselah T., Ruane P.J., Gruener N., Abergel A., Mangia A., Lai C.-L., Chan H.L.Y. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N. Engl. J. Med. 2015;373:2599–2607. doi: 10.1056/NEJMoa1512610. - DOI - PubMed
    1. Forns X., Lee S.S., Valdes J., Lens S., Ghalib R., Aguilar H., Felizarta F., Hassanein T., Hinrichsen H., Rincon D., et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 2017;17:1062–1068. doi: 10.1016/S1473-3099(17)30496-6. - DOI - PubMed
    1. World Health Organization . The Draft WHO Global Hepatitis Strategy. World Health Organization; Geneva, Switzerland: 2016. Towards the elimination of hepatitis B and C by 2030.
    1. Chen Z.W., Li H., Ren H., Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data. Sci. Rep. 2016;6:20310. doi: 10.1038/srep20310. - DOI - PMC - PubMed
    1. Kwo P., Gitlin N., Nahass R., Bernstein D., Rojter S., Schiff E., Davis M., Ruane P.J., Younes Z., Kalmeijer R. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J. Hepatol. 2015;62:S270. doi: 10.1016/S0168-8278(15)30168-9. - DOI

Publication types

Substances